Table 1 Baseline characteristics and antibody titers among patients treated with anti-fibrotic treatment and matched control
Anti-fibrotic Treatment (n = 40) | Matched control (n = 40) | P value | |
|---|---|---|---|
Age, median (IQR), y | 71 (67–75) | 69 (63–72) | 0.02 |
Male sex (%) | 27 (67.5) | 16 (40) | 0.01 |
IgG titer, median (IQR), Au/ml | 361.10 (207–811) | 820.75 (459–1313) | 0.001 |
IgG titer GMT (SD) | 441.26 ± 3.15 | 835.41 ± 2.07 | 0.004 |
Seropositive (%) | 40 (100) | 40 (100) | 1.0 |
Days post vaccination, median (IQR) | 173 (168–182) | 128.55 (123–142) | < 0.001 |